Rovida Investment Management Ltd Purchases 1,000,000 Shares of ASP Isotopes Inc. $ASPI

Key Points

• Rovida Investment Management increased its stake in ASP Isotopes by 45.5%, buying 1,000,000 shares to hold 3,200,000 shares (about 3.43% of ASPI, valued at ~$30.7M), making the position its 7th largest holding.
• Analysts are mixed: Cantor Fitzgerald initiated coverage with an "overweight" $13 target and Canaccord reiterates a buy $11 target, while Weiss Ratings maintains a sell; the consensus rating is "Hold" with an average target of $13.00.
• Insiders have been selling recently—CFO Heather Kiessling sold 80,000 shares at $5.80 and CEO Robert Ainscow sold 8,438 shares at $6.20—and insiders now own about 14.4% of the stock.

Rovida Investment Management Ltd lifted its position in ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 45.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,200,000 shares of the company's stock after acquiring an additional 1,000,000 shares during the quarter. ASP Isotopes makes up about 3.5% of Rovida Investment Management Ltd's holdings, making the stock its 7th biggest holding. Rovida Investment Management Ltd owned 3.43% of ASP Isotopes worth $30,688,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ASPI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ASP Isotopes by 9.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company's stock valued at $148,000 after purchasing an additional 2,709 shares in the last quarter. Bank of Montreal Can raised its position in ASP Isotopes by 8.0% during the second quarter. Bank of Montreal Can now owns 27,000 shares of the company's stock valued at $199,000 after buying an additional 2,000 shares during the period. Rathbones Group PLC lifted its stake in ASP Isotopes by 1.1% in the 2nd quarter. Rathbones Group PLC now owns 208,149 shares of the company's stock worth $1,532,000 after acquiring an additional 2,220 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in ASP Isotopes by 127.1% during the 2nd quarter. SBI Securities Co. Ltd. now owns 21,279 shares of the company's stock worth $157,000 after acquiring an additional 11,909 shares during the period. Finally, Geode Capital Management LLC grew its stake in ASP Isotopes by 7.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,348,072 shares of the company's stock valued at $9,924,000 after acquiring an additional 94,751 shares in the last quarter. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ASPI. Cantor Fitzgerald started coverage on shares of ASP Isotopes in a research report on Thursday, December 4th. They issued an "overweight" rating and a $13.00 price target for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $11.00 price objective on shares of ASP Isotopes in a research note on Monday, November 24th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, ASP Isotopes presently has a consensus rating of "Hold" and an average target price of $13.00.

Insider Buying and Selling

In related news, CFO Heather Kiessling sold 80,000 shares of ASP Isotopes stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $5.80, for a total value of $464,000.00. Following the completion of the sale, the chief financial officer owned 732,500 shares of the company's stock, valued at approximately $4,248,500. The trade was a 9.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert Ainscow sold 8,438 shares of the company's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $6.20, for a total transaction of $52,315.60. Following the completion of the sale, the chief executive officer owned 1,546,255 shares of the company's stock, valued at $9,586,781. This represents a 0.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.40% of the stock is owned by insiders.

ASP Isotopes Stock Down 3.8%

Shares of ASP Isotopes stock opened at $5.11 on Friday. The firm has a market cap of $566.39 million, a price-to-earnings ratio of -3.93 and a beta of 3.55. The stock has a 50-day simple moving average of $6.22 and a 200-day simple moving average of $7.72. ASP Isotopes Inc. has a 52-week low of $3.71 and a 52-week high of $14.49. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.